Neoadjuvant Aumolertinib for Unresectable Stage III EGFR-Mutant Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial

This single-arm, Phase II trial assessed the feasibility of neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant NSCLC.